bioRxiv Science⌕ Search

Biology subjects

Firoozbakht, F.

Publications and source records attributed to Firoozbakht, F..

2 recordsLinked to original sources

NetMedGPT - A network medicine foundation model for extensive disease mechanism mining and drug repurposing

Network medicine leverages large biomedical knowledge graphs (KGs) to model disease mechanisms and identify therapeutic opportunities. However, most deep learning approaches that use KGs in biomedicine remain task-specific, limiting their ability to generalize across diverse applications within a unified framework. Here, we introduce NetMedGPT, a transformer-based foundation model trained on a large-scale biomedical KG using masked token prediction. By learning contextualized representations of biomedical nodes, NetMedGPT enables unified, zero-shot inference across different drug discovery tasks. Specifically, in five tasks, i.e., predicting the association of drugs with indications, targets, adverse drug reactions, contraindications, and off-label uses, NetMedGPT consistently outperforms all specialized baselines, achieving area under the precision-recall curve gains of between 2.2% and 26%. When evaluated on independent external datasets, NetMedGPT outperformed baseline on an expert-curated clinical indications set and also preferentially prioritized clinically relevant drug-disease pairs in ClinicalTrials.gov. NetMedGPTs generative capability further supports the construction of mechanistically plausible subnetworks offering biological insights. NetMedGPT provides a unified foundation model for network medicine that supports scalable hypothesis generation and provides potential to accelerate drug repurposing. We further provided an interactive interface (https://prototypes.cosy.bio/chatnetmedgpt/) that allows users to obtain model inferences through natural-language queries.

bioinformatics↗

DREAMER: Exploring Common Mechanisms of Adverse Drug Reactions and Disease Phenotypes through Network-Based Analysis

Adverse drug reactions (ADRs) are a major concern in clinical healthcare, significantly affecting patient safety and drug development. The need for a deeper understanding of ADR mechanisms is crucial for improving drug safety profiles in drug design and drug repurposing. This study introduces DREAMER (Drug adverse REAction Mechanism ExplaineR), a novel network-based method for exploring the mechanisms underlying adverse drug reactions and disease phenotypes at a molecular level by leveraging a comprehensive knowledge graph obtained from various datasets. By considering drugs and diseases that cause similar phenotypes, and investigating their commonalities regarding their impact on specific modules of the protein-protein interaction network, DREAMER can robustly identify protein sets associated with the biological mechanisms underlying ADRs and unravel the causal relationships that contribute to the observed clinical outcomes. Applying DREAMER to 649 ADRs, we identified proteins associated with the mechanism of action for 67 ADRs across multiple organ systems, e.g., ventricular arrhythmia, metabolic acidosis, and interstitial pneumonitis. In particular, DREAMER highlights the importance of GABAergic signaling and proteins of the coagulation pathways for personality disorders and intracranial hemorrhage, respectively. We further demonstrate the application of DREAMER in drug repurposing and propose sotalol (targeting KCNH2), ranolazine (targeting SCN5A, currently under clinical trial), and diltiazem (indicated drug targeting CACNA1C and SCN3A) as candidate drugs to be repurposed for cardiac arrest. In summary, DREAMER effectively detects molecular mechanisms underlying phenotypes emphasizing the importance of network-based analyses with integrative data for enhancing drug safety and accelerating the discovery of novel therapeutic strategies.

systems biology↗